Monthly Archives: February 2020

Resveratrol to Witness Growth Acceleration During 2018 2026 – Jewish Life News

Posted on by

According to a report published by TMR market, the Resveratrol economy is expected to witness a CAGR growth of XX% within the forecast period (2019-2029) and reach at a value of ~US$ at the ending of 2029. The macro-economic and micro elements which are predicted to influence the trajectory of this market are studied in the presented market study.

Light on the raw material throws Suppliers, vendors, manufacturers, and market consumers at the markets value chain. Furthermore, the political and economic scenarios of regions and its effect on the Resveratrol market are discussed within the accounts.

Critical Insights enclosed from this report:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=59604

Competitive Outlook

Light onto the throws Business prospects of prominent players operating from the Resveratrol sector. The item pricing plans, marketing stations that were preferred , product portfolio of most players, and promote presence of each and every company is contained in the report. The dominant players covered in the report include Business, Business two, Business 3, and Company 4.

Regional Assessment

The presented market study sheds light on the Marketplace Scenario in various markets. Furthermore, the governmental and regulatory policies to the prospects of the Resveratrol market in each regions effect is analyzed in the report.

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note: Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=59604

The report Suits the questions pertaining To the Resveratrol economy:

Reasons TMR Sticks out

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=59604

Read this article:
Resveratrol to Witness Growth Acceleration During 2018 2026 - Jewish Life News

Research Roundup: Antibiotics Linked to Birth Defects and More – PharmaLive

Posted on by

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Some Antibiotics Prescribed During Pregnancy Linked to Birth Defects

Researchers at the University College Londonfound that children of mothers prescribed macrolide antibiotics in the first trimester of pregnancy were at increased risk of major birth defects. The research was published in The BMJ. The birth defects include major malformations such as heart and genital defects, and four neurodevelopment disorders, cerebral palsy, epilepsy, ADHD, and autism spectrum disorder.

Macrolide antibiotics are used to treat a wide variety of bacterial infections and are among the most frequently prescribed antibiotics during pregnancy in Western countries, said Heng Fan, PhD candidate at UCL Great Ormond Street Institute of Child Health, and lead author of the study. This work builds on previous evidence of rare but serious adverse outcomes of macrolide use, especially for unborn babies. These adverse outcomes were assumed to be associated with the arrhythmic effect of macrolides, and policy advice about their use in pregnancy varies.

The investigators analyzed data from 104,605 children born in the UK from 1990 to 2016 from the Clinical Practice Research Datalink (CPRD), with a median follow-up of 5.8 years after birth. An additional 82,314 children whose mothers were given macrolides or penicillins before pregnancy and 53,735 who were siblings of children in the study acted as control cohorts. Major malformations were seen in 186 children of 8,632 whose mothers received macrolides at any point during pregnancy and 1,666 of 95,973 children whose mothers were dosed with penicillins during pregnancy. The researchers concluded that macrolides during the first three months of pregnancy were associated with an increased risk of any major malformation compared to penicillin.

The Mediterranean Diets Key Ingredient for Extending Lifespan

The Mediterranean diet has been noted for being heart-healthy and potentially improving lifespanheavy on fish, fruits, vegetables, grains, olive oil and red wine. Much research suggested the resveratrol found in red wine was the major contributor, but new research suggests it is actually the fat found in olive oil that activated a pathway known to increase lifespan and prevent aging-related diseases. It appears that the fat gets stored in lipid droplets and when the fat is broken down during exercise or fasting, the signaling and health benefits occur.

What Facebook and Genomes Have in Common

Computational biologists at Carnegie Mellon Universitytook an algorithm used to study social networks like Facebook and adapted it to identify how DNA and Proteins behave in communities inside the cell nucleus. Proximity is a factor, because genes controlled by the same regulatory proteins benefit from being close to each other, but others can be relatively far apart but drawn together via shared interests. The MOCHI algorithm analyzes the spatial arrangement of all the genes and transcription factor proteins in a nucleus based on genome-wide chromosome interactions and global gene regulatory networks.

A 3D Atomic Scale Map of the 2019 Coronavirus

Investigators at the University of Texas at Austin and the NIH created the first 3D atomic scale map of the 2019 novel coronavirus. They used AMETEK Gatans K3 camera to map part of the virus called the spike protein, which is how the virus penetrates the host cells. The breakthrough should allow for more rapid vaccine and therapy development.

How Lung Cancer Cells Suck Up Energy

Researchers working with human lung cancer cells discoveredhow they modulate their energy consumption based on their surroundings. In addition, they discovered how cancer cells override those factors to maximize their energy use. They identified a protein called TRIM21 that appears able to prevent the degradation of metabolic enzymes, resulting in cancer cells keeping their metabolism high. Being able to interrupt this pathway could lead to new approaches to cancer therapies.

New Hope for Muscular Dystrophy

Although there are now a couple therapies on the market for Duchenne muscular dystrophy (DND), it is still incurable. Researchers at the University of Pennsylvania School of Medicinerecently identified a group of small molecules that might lead to new treatments. The compounds eased repression of a specific gene, utrophin, in mouse muscle cells. This allows the body to produce more utrophin protein, which can be substituted for dystrophin, the protein whose absence causes DMD.

Were trying to find therapies that will restore a patients muscle function without resorting to gene therapy, said Tejvir S. Khurana, the studys senior author and professor of Physiology. Increasing utrophin is a major focus of muscular dystrophy research. While, ideally, we would replace the missing dystrophin in patients, there are a number of technical and immunological problems associated with this approach.

One is simply that the dystrophin gene is the largest in the body, and cant be fit into the viruses used for gene therapy. Most approaches along those lines use truncated dystrophin genes or other means to introduce a partial dystrophin gene or gene product. The other problem is that because the human body of DMD patients doesnt have regular amounts or types of dystrophin, introducing dystrophin to the body often stimulates an immune response as the immune system reacts to it as an invader.

See the original post:
Research Roundup: Antibiotics Linked to Birth Defects and More - PharmaLive

13 Foods that Increase Fertility – Glamour

Posted on by

Some women choose to give up alcohol and other substances in order to help with conception, but did you know that there are certain foods that increase fertility? While the idea of fertility foods might feel a little foreign, the way you nourish your body matters when youre trying to conceive. Many women dont realize that lifestyle, stress, and food can play a significant role in infertility, says Jayne Williams, a certified integrative health and nutrition expert. Eating a diet that supports fertility includes whole foods, a healthy balance of lean protein, healthy fats, and fiber that can help boost your gut microbe, regulate hormones, and lower stress levelsall three are important to prep your body for pregnancy.

When youre eating for reproductive health, foods that can help lower stress hormones and increase blood flow to the uterus are the ticket, says Lindsey Becker, a fertility chef, certified health coach, and founder of Farm Cut. From salmon and walnuts, which have been shown to reduce surges of stress hormones, to beetroots, which are rich in resveratrol and nitrates and are known to improve blood flow to the uterus to help with embryo implantation, she says, here are 13 foods that increase fertilityand how to eat them. Bon apptit!

You probably already love your guac, amirite? Turns out, avocados are a great fertility food. They are a fantastic source of vitamin E, which studies have shown can be beneficial in improving the lining of the uterus, says Becker.

Williams agrees. Avocados are one of my go-to favorites for healthy fat. They also happen to be high in potassium, folate, and vitamin K, which helps your body to properly absorb other vitamins.

One way to enjoy your avocado is to have avocado toast topped with pomegranate seeds for added antioxidants, Becker recommends. Another great treat is to simply add a quarter of an avocado to your daily smoothieit makes it creamier and adds a certain richness that will make your smoothie taste more like a milkshake. (Almost.) Plus, dont forget the guacamole, Williams says, which can be made simply with jalapeos, cilantro, and onion.

We should all be having dark green vegetables daily, but theyre especially important when youre trying to get pregnant. Kale, spinach, and Swiss chard contain essential prenatal nutrients like calcium, iron, and folate (which also helps protect against birth defects), not to mention tons of vital daily dietary fiber, says Williams.

There are endless ways to include your greens into your daily diet, Williams says. From eating them raw in salads, sauted, blanched, and steamed. Kale can also be roasted to make kale chips, while spinach can be added to smoothies since it has a very mild flavor. Just a small handful will do, she says.

Beets and their greens are an underestimated vegetable if I ever saw one. Beetroots are known to improve blood flow to the uterus to help with embryo implantation, explains Becker. Eating a diet rich in beets during IVF treatment is especially helpful. Thats why they should definitely be added to your fertility foods list, even if youre not going through IVF.

Theyre pretty simple to prepare too. All you need to do is treat them like potatoes: Wash and scrub them clean, and then toss them with olive oil, salt, and pepper. Wrap a whole one in tin foil and roast at 400 for about an hour, until tender, or shorten your time by chopping them into small pieces. Then, once theyre cooked, rub the skin off with your thumbs (wearing gloves because, otherwise, your hands will end up pink for hours) and toss with a little red wine vinegar and olive oil for a scrumptious salad. You can also add some sweet potatoes to this salad for an extra boost.

Read the rest here:
13 Foods that Increase Fertility - Glamour

Scientists shed light on the health benefits of olive oil – Medical News Bulletin

Posted on by

A recent study investigated the associationbetween olive oil and decreased risk of aging-related diseases.

Olive oil is a primary source of fat in the Mediterranean diet. It consists of monosaturated fatty acids (MUFAs), the healthy fat that lowers cholesterol levels. It is rich in antioxidants, which help prevent cellular damage and decrease the risk of developing chronic diseases, such as cancer.

The Mediterranean diet is known for its wide range of health benefits, which include reducing overall mortality and aging-related diseases. Several studies suggest red wine as the main contributor in promoting the health benefits of the Mediterranean diet. This is because red wine contains resveratrol, a compound that activates SIRT1, a cellular pathway associated with extending lifespan and preventing aging-related diseases. However, in a recent study, researchers from the University of Minnesota identified olive oil as the key component in the Mediterranean diet that may contribute to lowering the risk of aging-related diseases and improve lifespan.

In the study, published in Molecular Cell, male mice, aged between six and eight weeks fed eithera diet that included olive oil, or a control diet that did not contain oliveoil, for twelve weeks. The control diet included soybean oil and lard. At theend of the feeding experiments, the mice were fasted for around sixteen hoursbefore their tissue and serum samples were collected.

The study reports that the fats in olive oil activated the SIRT1 pathway in the cells. These findings suggest that olive oil might play a key role in increasing lifespan and preventing aging-related diseases. According to the researchers, the consumption of olive oil by itself was not enough to gain its health benefits. The findings suggest that the effects of olive oil may be most noticeable when it is consumed in combination with fasting, exercising, and limiting caloric intake.

According to the study author, Dr. Mashek, the fat in olive oil is stored in lipid droplets, microscopic organelles in cells that provide storage for fats. Dr. Mashek suggests that when fat is broken down during fasting or exercising, the effects of the signalling in cells and the health benefits of olive oil are realized.

Future research will involve translating the findings tohumans with the aim of discovering new drugs or to tailor dietary regimens thatwill improve health outcomes in both the short-term and long-term.

Written byRanjani Sabarinathan, MSc

References:

Najt CP, Khan SA, Heden TD et al. (2020). Lipid Droplet-Derived Monounsaturated Fatty Acids Traffic via PLIN5 to Allosterically Activate SIRT1. Molecular Cell. doi: 10.1016/j.molcel.2019.12.003

University of Minnesota researchers discover Mediterranean diet ingredient may extend life. (2020, February 21). Retrieved from https://www.eurekalert.org/pub_releases/2020-02/uomm-uom022120.php

Image byPezibearfromPixabay

View original post here:
Scientists shed light on the health benefits of olive oil - Medical News Bulletin

Why Lakeland Industries, Alpha Pro Tech, and Vir Biotechnology Briefly Skyrocketed and Crashed Today – Motley Fool

Posted on by

What happened

Investors in Lakeland Industries (NASDAQ:LAKE), Alpha Pro Tech (NYSEMKT:APT), and Vir Biotechnology(NASDAQ:VIR) are experiencing a wild end to the trading week. Shares of these companies rose as much as 40%, 65%, and 20%, respectively, in early-morning trading on Friday. However, all three of them have since reversed course and have come crashing back down to earth. At their lowest points, they were down 13%, 34%, and 36%, respectively.

As of 2:57 p.m. EST, shares of Lakeland Industries up about 1% while shares of Alpha Pro Tech and Vir Biotechnology were down 9% and 30%, respectively.

You're probably aware that fears of the spread of the COVID-19 (the illness caused by a novel coronavirus) are wreaking havoc on the public market this week. TheDow Jones Industrial Average(DJINDICES: ^DJI),S&P 500(SNPINDEX: ^GSPC), andNasdaq Compositehave all dropped more than 10% from their recent highs in the last five days. That's a remarkably big move in such a short period of time.

At the same time, traders have been going crazy for any stock that is poised to benefit from the coronavirus. Lakeland Industries,Vir Biotechnology, andAlpha Pro Tech have all been identified as "Coronavirus stocks" this week and have gone parabolic in response.

Image source: Getty Images.

Lakeland Industries, which sells industrial protective clothing such ascoveralls and laboratory coats, has surged 47% in the last five days. The only news out of the company during that time is that is participating in an upcoming investor conference. Traders are probably bidding up shares on the hope that demand for its products has surged in the last few weeks.

Vir Biotechnology, which is aclinical-stage immunology company, isup 158% in the last week. A lot of the sudden bullishness is traceable to the announcement that it has partnered with a Chinese drug maker to develop a potentialtreatment for Coronavirus.

Alpha Pro Tech's returns top them all. Like Lakeland Industries, Alpha Pro Tech sells protective apparel such as gowns, coveralls, face masks, and more. Shares of this normally sleepy stock are up an incredible 317% in the last five trading days, which is a remarkable move. Management announced yesterday that has booked $14 million in orders for its N-95 Face mask, which is a sizable order for the small-cap.

It's impossible for investors to know what the fallout from the coronavirus will be and how that will impact the markets. However, it's likely that stock prices are going to remain extremely volatile as long as thecoronavirus continues to dominate the headlines.

It might seem tempting to buy into stocks that could see a short-term benefit from the continued spread of the coronavirus disease, but that is probably unwise in the long term given that the virus will eventually be contained.

Personally, I had no interest in any of these companies prior to their recent jump, and I see no reason to be bullish on them today. That's why my plan remains to focus my time and capital on companies that are poised to grow rapidly even if it takes a long time for governments to get thecoronavirus under control.

Link:
Why Lakeland Industries, Alpha Pro Tech, and Vir Biotechnology Briefly Skyrocketed and Crashed Today - Motley Fool

WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 – Yahoo Finance

Posted on by

SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. ("Vir") (Nasdaq: VIR) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir's proprietary antibodies. WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. If the antibodies receive regulatory approvals, WuXi Biologics has the rights to commercialize therapies in Greater China, and Vir has the rights to commercialize therapies in all other markets worldwide.

Vir has identified a number of monoclonal antibodies (mAbs) that bind to SARS-CoV-2. These antibodies were isolated from individuals who had survived a Severe Acute Respiratory Syndrome (SARS) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

"We are acutely aware of the importance of moving rapidly in response to COVID-19," said George A. Scangos, Ph.D., CEO of Vir Biotechnology. "In the event that we are in a position to develop an antibody therapy, our agreement with WuXi Biologics enables us to accelerate advancement against this global threat."

"Both WuXi Biologics and Vir felt the great urgency to develop antibodies to treat global patients provided they work in the clinic. Our state-of-the-art technology platform and robust global-quality supply network make us uniquely qualified in expediting the development and manufacturing of these potential treatments," commented Chris Chen, Ph.D., CEO of WuXi Biologics. "Once again WuXi Biologics is collaborating with global biotech companies such as Vir to expedite biologics development to benefit patients worldwide."

About Vir's Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in the Democratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit http://www.wuxibiologics.com.

SOURCE WuXi Biologics

Go here to see the original:
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 - Yahoo Finance

Will Puma Biotechnology Break Out of Its Rut in 2020? – Motley Fool

Posted on by

Aside from an acquisition, earning marketing approval for a drug candidate is the single biggest event that can happen for a development-stage pharmaceutical company. It marks the beginning of the transition to commercial operations and tends to spark a celebration among investors. But sometimes the celebration is premature.

Puma Biotechnology (NASDAQ:PBYI) offers a particularly painful case study of what can go wrong after a promising drug product launches. The company's breast cancer drug, Nerlynx, was once widely expected to become a blockbuster (a drug that generates over $1 billion in annual sales), but severe side effects have led to high discontinuation rates among patients. Growth virtually stalled in 2019. The pharma stock has fallen over 90% since its peak in late 2017.

While the precipitous fall in the stock price has been terrible for shareholders, Puma Biotechnology has a realistic plan to get Nerlynx back to growth. What do investors need to watch to gauge progress in 2020?

Image source: Getty Images.

Nerlynx is approved as an adjuvant treatment for individuals with early-stage HER2-positive breast cancer who have completed treatment with Herceptin. It disrupts cell signalling processes involved in tumor growth that are enabled by proteins in the HER family.

While Nerlynx is only approved for 12 months of use, most of the first patients to receive the drug discontinued treatment significantly sooner (usually in the first month) due to severe diarrhea. That curtailed year-over-year growth figures beginning in the fifth quarter after launch. Case in point: Full-year 2019 revenue grew just 5% compared to 2018, the drug's first full year on the market.

Investors and Wall Street analysts have been less than forgiving -- and for good reason. But investors would also have to acknowledge that Puma Biotechnology managed the setback for Nerlynx relatively well.

Last year, the business focused on growing product sales (albeit slowly), reducing operating expenses, advancing international partnerships, funding several studies to potentially expand the drug's use, and developing clinically validated regimens for reducing side effects. All of those efforts led to a respectable year of operations in 2019.

Metric

2019

2018

Change (YOY)

Product revenue

$211.6 million

$200.5 million

5%

Total revenue

$272.3 million

$251.0 million

8%

Operating expenses

$311.4 million

$345.7 million

(10%)

Operating income

($39.1 million)

($94.7 million)

N/A

Data source: Company press release. YOY = year over year.

Wall Street isn't looking for respectable operations. Analysts want to see a return to growth before reconsidering the company's $450 million market valuation. What can Puma Biotechnology do to deliver on those demands?

Investors will be watching two areas in 2020 to gauge progress:

In late 2019, Puma Biotechnology released data from a study evaluating what antidiarrheal combinations could effectively reduce the severity of diarrhea. Whereas a combination of Nerlynx and loperamide resulted in 20.4% of individuals stopping treatment due to diarrhea and 44.5% discontinuing treatment for any reason (including diarrhea), a combination of Nerlynx, loperamide, and budesonide lowered those discontinuation rates to just 10.9% and 20.3%, respectively.

More promising, doctors found that combining a dose escalation regimen of Nerlynx with loperamide led to just 3.3% of individuals stopping treatment due to diarrhea and 20% discontinuing for any reason.

Puma Biotechnology was quick to put the knowledge into action. In the fourth quarter of 2019, nearly 29% of new patients were started at a reduced dose with the goal of increasing it over the course of treatment. That compares to only 6.6% of patients starting at the reduced dose in the prior-year period.

Investors cannot celebrate yet. During the fourth-quarter 2019 earnings conference call, Puma Biotechnology said it expected the escalating dosing regimen will lower the number of bottles sold initially with an "increase in the potential revenue per patient" in future quarters. In other words, it will take time to know if the new dosing schedule will have the intended effect.

Puma Biotechnology is also eager to expand the use of Nerlynx, which is the only asset in its portfolio and pipeline. There are a number of international regulatory decisions expected soon. Most markets are small, although partner Pierre Fabre launched Nerlynx in select European countries at the end of 2019, while regulators in China are expected to approve the drug in the first half of 2020.

While international sales could create a decent royalty revenue stream for Puma Biotechnology, the company is forging ahead with expanded use in the U.S., where it owns full rights to the drug.

Event

Significance

Decision on supplemental New Drug Application (sNDA) for Nerlynx and Xeloda (a chemotherapy) as third-line treatment for HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration (FDA) is expected to hand down a decision by April 2020. Analysts expect the indication could achieve peak annual sales of $300 million.

Phase 2 results for Control

Positive results over a longer duration could bolster confidence in the new dose escalation regimen. Results expected by the end of 2020.

Phase 2 results for Summit

Exploring the use of Nerlynx in HER2-mutated solid tumor cancers, including breast cancer and cervical cancer. Results expected by the end of 2020.

Data source: Company presentation.

Puma Biotechnology expects to explore additional expansions in HER2-positive breast cancer and HER2-mutated solid tumor cancers, but earning marketing approval for the Nerlynx and Xeloda combination therapy is the nearest and most important potential milestone.

It has certainly been easy to write off Puma Biotechnology in recent years. Nerlynx stumbled in the second full year of its launch due to high discontinuation rates and, considering it's the only asset owned by the company, investors headed for the exits for good reason.

While investors should remain skeptical of the company's ability to pull itself out of its rut, there does appear to be a path forward. The question is whether success is defined by Nerlynx returning to its former blockbuster potential or something far less than that. Unfortunately, investors won't really have enough data points for a few more quarters, although getting the sNDA approved in April could provide a significant boost for the beaten-down stock.

Read the original post:
Will Puma Biotechnology Break Out of Its Rut in 2020? - Motley Fool

Investors Endure Wild Ride in This Biotech Taking on COVID-19 – Motley Fool

Posted on by

Vir Biotechnology (NASDAQ:VIR) may not be a familiar name to many investors. This relatively young biotech went public last October. Backed by infamous investor SoftBank (of WeWork fame) among others, investors in Vir find themselves in a situation where they truly are betting on the jockey. The seasoned biotech veteran George Scangos helms the company following his prior leadership at Biogenand Exelixis. An experienced team surrounds him, supported by a board of directors filled with seasoned executives.

Vir's mission to eradicate the world of infectious diseases makes it a natural candidate to enter the fray pursuing COVID-19 interventions. Companies are racing to be the first to develop a vaccine and a treatment to stymie the spread of the coronavirus, so investors should familiarize themselves with Vir.

Image Source: Getty Images.

Following an IPO priced at $20 per share, Vir's stock stumbled and spent most of the fall in the $12 and $13 range.The stock took on a new life doubling in price in the second half of January. The stock retreated from this short-lived run above $26 back down to the high teens in the middle of February.

In the last week, the stock has gone parabolic. It closed above $60 per share this week and even broke $70 in pre-market trading on Friday. That's a more than four-fold increase from the start of the year and five times what it traded for most of last year.

Then, boom. Friday morning stock precipitously fell below $40 per share immediately after the market opened. Roughly $2 billion in valuation wiped out in minutes. Within hours, the stock gained back $1 billion in value only to lose it again. This tremendous volatility makes for a trader's playground but can wrack the nerves of fundamental investors.

Image Source: Getty Images.

My issue has less to do with the research and development per se and more with the valuation. Vir's market cap swelled to more than $6 billion at its peak. Personally, I felt its prior valuation in the $1 billion to $2 billion range was pricey for a company with two early-stage clinical candidates. However, the giant leap in valuation does not appear to be based on new data emerging from Vir's R&D efforts. It stems from an announcement on Feb. 25 that Vir teamed up with WuXi Biologics to develop antibodies to treat the spreading COVID-19 (the coronavirus 2019).

It seems like every few hours, news breaks of more confirmed coronavirusinfections in new locales. The pandemonium continues to swell causing a backlash through the economy and eviscerating stock markets. I commend Vir and WuXi, one of the leading Chinese biotech companies, for allocating resources to tackle this growing challenge. The key will be whether the two drug developers can advance a meaningful therapy and do so in a fairly rapid timeframe.

The company maintains a certain degree of implied credibility because Vir is backed by marquee investors, including the Gates Foundation, it's led by seasoned drug developers, and it boasted a $1 billion-plus market cap prior to the COVID-19 news. It seems reasonable to believe that the company's platform technology can deliver COVID-19-specific antibodies for testing. The timing along with safety and potency remain big question marks for now.

I highlight the credibility factor because some small and micro-cap biotechs are jumping on the COVID-19 bandwagon. Some of these smaller entities are well-intentioned while other unscrupulous groups will never undertake meaningful R&D efforts. This latter cohort aims to piggyback on the momentum of the situation. If the stocks spike, these companies usually raise capital to continue operations. The SEC issued a warning to investors to beware of coronavirus scams. The SEC even halted trading in one such penny stock last week.

I don't believe Vir falls into that category. I think the company will undertake a genuine effort and has lined up a reputable partner. However, in the absence of data, predicting if any product will emerge come from the R&D efforts remains challenging. Further, guessing the value of a COVID-19 treatment is difficult. Is it worth $1 billion in market cap, half of that, or multiples more? Nobody really knows. It will depend on how widespread the outbreak is at the time of commercialization, which countries are most in need, and what price the drug will ultimately command.

Biotech investing is not for the faint of heart. The volatility in Vir's stock and high valuation make me cautious. Additionally, Vir faces competition such asGilead Sciences (NASDAQ:GILD), which kicked off two phase 3 clinical trials this week for its promising drug aimed at COVID-19. For now, I will watch Vir from the sidelines and wish the team well on developing a successful treatment.

Originally posted here:
Investors Endure Wild Ride in This Biotech Taking on COVID-19 - Motley Fool

Industry Breakdown: Where Does BIO-TECHNE Corp (TECH) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted on by

BIO-TECHNE Corp (TECH) is near the top in its industry group according to InvestorsObserver. TECH gets an overall rating of 58. That means it scores higher than 58 percent of stocks. BIO-TECHNE Corp gets a 67 rank in the Biotechnology industry. Biotechnology is number 24 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 58 means the stock is more attractive than 58 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

BIO-TECHNE Corp (TECH) stock is trading at $187.99 as of 12:50 PM on Friday, Feb 28, a loss of -$5.02, or -2.6% from the previous closing price of $193.01. The stock has traded between $186.18 and $192.94 so far today. Volume today is less active than usual. So far 126,053 shares have traded compared to average volume of 176,091 shares.

To see the top 5 stocks in Biotechnology click here.

Go here to see the original:
Industry Breakdown: Where Does BIO-TECHNE Corp (TECH) Stock Fall in the Biotechnology Field? - InvestorsObserver

Biotechnology and Pharmaceutical Services Outsourcing Market 2020 Size, Trends, Global Growth, Industry Regional Segmentation, Top Manufactures and…

Posted on by

Biotechnology and Pharmaceutical Services Outsourcing Market 2020-2025 Industry research report covers the market landscape and its growth prospects over the coming years, the report also brief deals with the product life cycle, comparing it to the relevant products from across industries that had already been commercialized details the potential for various applications, discussing about recent product innovations and gives an overview on potential regional market.

Get Sample Copy of this Report https://www.orianresearch.com/request-sample/1440277

Based on the Biotechnology and Pharmaceutical Services Outsourcing industrial chain, this report mainly elaborates the definition, types, applications and major players of Biotechnology and Pharmaceutical Services Outsourcing market in details. Deep analysis about market status (2014-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2024), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included. From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Biotechnology and Pharmaceutical Services Outsourcing market.

The Biotechnology and Pharmaceutical Services Outsourcing market can be split based on product types, major applications, and important regions.

Major Players in Biotechnology and Pharmaceutical Services Outsourcing market are:o Inspired Pharmao GMP Pharmaceuticalso Concept Heidelberg GmbHo Quality Contexto RSSLo QuintilesIMSo Management Forumo Quantic Groupo Parexel International Corporationo Lachman Associates

Major Regions that plays a vital role in Biotechnology and Pharmaceutical Services Outsourcing market are:o North Americao Europeo Chinao Japano Middle East & Africao Indiao South Americao Others

Most important types of Biotechnology and Pharmaceutical Services Outsourcing products covered in this report are:o Consultingo Auditing & Assessmento Regulatory Affairso Product Maintenanceo Product Design & Developmento Product Testing & Validationo Training & Educationo Others

Most widely used downstream fields of Biotechnology and Pharmaceutical Services Outsourcing market covered in this report are:o Regenerative Medicineo Biobankingo Drug Discovery

Order a copy of Global Biotechnology and Pharmaceutical Services Outsourcing Market Report @https://www.orianresearch.com/checkout/1440277

There are 13 Chapters to thoroughly display the Biotechnology and Pharmaceutical Services Outsourcing market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

Chapter 1: Biotechnology and Pharmaceutical Services Outsourcing Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.Chapter 2: Biotechnology and Pharmaceutical Services Outsourcing Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Biotechnology and Pharmaceutical Services Outsourcing.Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Biotechnology and Pharmaceutical Services Outsourcing.Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Biotechnology and Pharmaceutical Services Outsourcing by Regions (2014-2020).Chapter 6: Biotechnology and Pharmaceutical Services Outsourcing Production, Consumption, Export and Import by Regions (2014-2020).Chapter 7: Biotechnology and Pharmaceutical Services Outsourcing Market Status and SWOT Analysis by Regions.Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Biotechnology and Pharmaceutical Services Outsourcing.Chapter 9: Biotechnology and Pharmaceutical Services Outsourcing Market Analysis and Forecast by Type and Application (2020-2024).Chapter 10: Market Analysis and Forecast by Regions (2020-2024).Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.Chapter 12: Market Conclusion of the Whole Report.Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

OUR OTHER REPORTSGlobal Nursing Dresses Market Data Survey Report 2015-2025http://www.marketwatch.com/story/nursing-dresses-market-2020-industry-size-share-growth-rate-2025-forecast-and-manufacturers-analysis-report-2020-02-05

Global Neutron Generators Market Data Survey Report 2015-2025

http://www.marketwatch.com/story/neutron-generators-market-identification-and-detailed-analysis-on-key-market-dynamics-restraints-opportunities-and-challenges-influencing-the-growth-of-the-market-2020-02-05

Global Nursing Dresses Market Data Survey Report 2015-2025

Contact UsRuwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (415) 830-3727 | UK: +44 020 8144-71-27Email: [emailprotected]

About UsOrian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ Industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

More here:
Biotechnology and Pharmaceutical Services Outsourcing Market 2020 Size, Trends, Global Growth, Industry Regional Segmentation, Top Manufactures and...

Polymerase Chain Reaction (PCR) Market: Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global Market – BioSpace

Posted on by

Rising at an impressive single digit CAGR, the global polymerase chain reaction market is predicted to attain a value of almost US$7.0 bn by 2026-end. Factors enabling the market to rise so impressively is the increasing research and development expenditure, gigantic strides made in the domain of pharmacogenomics, and rising trend of self-diagnosis of ailments. The global polymerase chain reaction (PCR) market is also being boosted by new technologies for diagnosis of cancer.

Further, research and development in advanced molecular biology, forensic science, and genetic engineering are also predicted to positively influence the global polymerase chain reaction (PCR) market. The only hurdle emergence of the alternative next-generation sequencing. The expensiveness of certain commercial PCR technologies is also dampening sales in the market to a degree.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=830

A few noticeable trends which key stakeholders in the global polymerase chain reaction (PCR) market need to keep in mind are as follows:

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, Request for Custom Research at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=830

Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global PCR Market in 2017

The PCR technique has been found to be useful in pharmaceutical and biotechnology research activities as well as microbial quality testing. The technique is also applied in genetic engineering. Genetic engineering is the key driver for the global PCR market. It is used to identify genes related to certain phenotypes including genetic disorders. Regular testing of the microbial load of raw materials and finished products is an important process in the pharmaceutical & biotechnology industry. Sophisticated analytical methods such as polymerase chain reaction (PCR) have been widely applied for quality control analysis in the pharmaceutical sector.

Market in Asia Pacific to Expand at a High CAGR

Molecular diagnosis has revolutionized the modern diagnosis technology. PCR has become a method of choice in early and accurate detection of diseases. Expansion by leading manufacturers of PCR products in the Asia Pacific region by strengthening of the distribution network and new product launches in developing countries of Asia Pacific are key factors likely to drive the PCR market in the region during the forecast period.

Moreover, rise in the incidence of cancer and infectious diseases has resulted in increase in the demand for use of the PCR technique in clinical diagnosis of these diseases in Asia Pacific. For instance, according to the Korea Central Cancer Registry published in 2016, there were 217,057 cancer cases in South Korea in 2014. Moreover, in 2016, the WHO estimated that the Asia Pacific region has the second-highest number (i.e. 5.1 million) of people living with HIV across the world. Thus, Asia Pacific is expected to be the most lucrative market for PCR by 2026.

Buy Polymerase Chain Reaction (PCR) Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=830&ltype=S

Competition Landscape

Major players operating in the global PCR market are Bio-Rad Laboratories, Inc., QIAGEN N.V., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc. Becton, Dickinson and Company, Abbott, Siemens Healthcare GmbH (Siemens AG), bioMrieux SA, Danaher Corporation, and Agilent Technologies. Key players are expanding their product portfolio through mergers and acquisitions and partnerships and collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

More Trending Reports by Transparency Market Research -

Life Science Instrumentation Market: The global life science instrumentation market is projected to reach US$ 90 Bn by 2027, expanding at a single digit CAGR during the forecast period. Rise in prevalence and incidence rates of infectious diseases, high R&D investment by major players, and technological advancements are anticipated to drive the global market during the forecast period.

Molecular Diagnostic Market: Molecular diagnostics uses techniques such as nucleic acid amplification and hybridization for identification of microorganisms and presence of virulence factors. Various molecular assays have been developed using various technologies. These technologies increased the accuracy of the tests, producing rapid results.

Oligonucleotide Synthesis Market: According to the report by Transparency Market Research, the oligonucleotide synthesis market stood at US$1.65 bn in 2016 and is projected to reach a value of US$4.189 bn by the end of 2025. The market is likely to expand with a stellar CAGR of 11.2% over the forecast period from 2017 and 2025.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Polymerase Chain Reaction (PCR) Market: Pharmaceutical & Biotechnology Industry Segment Held a Major Share of the Global Market - BioSpace

Global Marine Biotechnology Market Expected to Grow with a CAGR of 8% During the Forecast Period, 2020-2024 – ResearchAndMarkets.com – Business Wire

Posted on by

DUBLIN--(BUSINESS WIRE)--The "Global Marine Biotechnology Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Global Marine Biotechnology Market 2020-2024

The analyst has been monitoring the global marine biotechnology market and it is poised to grow by USD 2.5 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period.

This report on the global marine biotechnology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in demand for biofuel. In addition, increasing application of seaweeds is anticipated to boost the growth of the global marine biotechnology market as well.

Key Trends for global marine biotechnology market growth

This study identifies increasing application of seaweeds as the prime reasons driving the global marine biotechnology market growth during the next few years.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Application

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4va2oa

See the original post here:
Global Marine Biotechnology Market Expected to Grow with a CAGR of 8% During the Forecast Period, 2020-2024 - ResearchAndMarkets.com - Business Wire

Puma Biotechnology Receives US FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer -…

Posted on by

Feb. 26, 2020 13:03 UTC

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The sNDA approval was based on results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine in patients with HER2-positive metastatic breast cancer who have received two or more prior anti-HER2-based regimens.

Although there have been many new treatment options for patients with HER2-positive breast cancer, patients still need additional treatment options once they progress, said Alan H. Auerbach, Chief Executive Officer and President of Puma. Based on the results of our NALA data, we believe NERLYNX could be a promising therapeutic opportunity for these patients.

Adam M. Brufsky, MD, Ph.D., of Magee-Womens Hospital and the Hillman Cancer Center at the University of Pittsburgh Medical Center, added, Together with the NALA investigators around the world, I am pleased to see the FDA approval of NERLYNX for the treatment of advanced HER2-positive metastatic breast cancer. This approval is based on data from the NALA trial, which we presented at ASCO last year, demonstrating that neratinib in combination with capecitabine offers a significant improvement over currently available therapies in this heavily pretreated patient population and can be added to NERLYNXs established role in the treatment of early breast cancer.

In the United States, NERLYNX is approved for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. In Europe, NERLYNX is approved for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX has also received approval for use in the extended adjuvant setting in Canada, Australia, Hong Kong, Singapore and Argentina.

In collaboration with its global licensing partners, Puma expects to seek approval of this second indication in all countries where NERLYNX is currently approved.

About NALA

Efficacy of neratinib in combination with capecitabine was investigated in NALA (NCT01808573), a randomized, multicenter, open-label, Phase III clinical trial in 621 patients with metastatic HER2-positive breast cancer who received two or more prior anti-HER2-based regimens in the metastatic setting. Patients were randomized (1:1) to receive neratinib 240 mg orally once daily on days 1-21 in combination with capecitabine 750 mg/m2 given orally twice daily on days 1-14 for each 21-day cycle (n=307) or lapatinib 1250 mg orally once daily on days 1-21 in combination with capecitabine 1000 mg/m2 given orally twice daily on days 1-14 for each 21-day cycle (n=314). Patients were treated until disease progression or unacceptable toxicity. The trial was conducted globally at sites in North America, Europe, Israel, Asia-Pacific and South America.

The main efficacy outcome measures were progression-free survival (PFS) as assessed by a blinded independent central review per RECIST v1.1 and overall survival (OS). Key secondary outcome measures were objective response rate (ORR) and duration of response (DOR). Treatment with neratinib in combination with capecitabine resulted in a statistically significant improvement in PFS (Hazard Ratio 0.76; 95% CI: 0.63, 0.93; p=0.0059) compared to treatment with lapatinib plus capecitabine. The PFS rate at 12 months was 29% (95% CI: 23, 35) for patients who received neratinib plus capecitabine vs 15% (95% CI: 10, 20) for patients who received lapatinib plus capecitabine; the PFS rate at 24 months was 12% (95% CI: 7, 18) vs 3% (95% CI: 1, 8), respectively.

Median OS was 21 months (95% CI: 17.7, 23.8) for patients who received neratinib in combination with capecitabine compared to 18.7 months (95% CI: 15.5, 21.2) for patients who received lapatinib in combination plus capecitabine (HR 0.88; 95% CI: 0.72, 1.07; p=0.2086). The ORR was 32.8% (95% CI: 27.1, 38.9) vs 26.7% (95% CI: 21.5, 32.4), respectively. Median duration of response was 8.5 months (95% CI: 5.6, 11.2) vs 5.6 months (95% CI: 4.2, 6.4), respectively.

The most common adverse reactions of any grade (>5%) in the neratinib plus capecitabine arm were diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms. The most frequently reported Grade 3 or 4 adverse reactions were diarrhea, nausea, vomiting, fatigue and decreased appetite.

The recommended neratinib dose for advanced or metastatic breast cancer is 240 mg (6 tablets) given orally once daily with food on days 1-21 of a 21-day cycle plus capecitabine (750 mg/m2 given orally twice daily) on days 1-14 of a 21-day cycle until disease progression or unacceptable toxicities.

About HER2-Positive Breast Cancer

Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy and is marketed in the United States as NERLYNX (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Forward-Looking Statements

This news release includes forward-looking statements. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including, once filed, Pumas Annual Report on Form 10-K for the year ended December 31, 2019. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005248/en/

View original post here:
Puma Biotechnology Receives US FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer -...

The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% – GlobeNewswire

Posted on by

New York, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Single-cell Analysis Market by Cell Type, Product, Technique, Application, End User - Global Forecasts to 2025" - https://www.reportlinker.com/p04579530/?utm_source=GNW However, the high cost of single-cell analysis products is expected to restrain the growth of this market to a certain extent during the forecast period.

The academic & research laboratories segment accounted for the largest market share in 2018On the basis of end user, the single-cell analysis market is segmented into academic and research laboratories, biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and cell banks and IVF centers.The academic and research laboratories segment accounted for the largest market share in 2018.

Factors such as growth in funding for life science research and the increasing number of medical colleges and universities are driving the growth of this end-user segment.

Flow cytometry is the largest technique segment of the single-cell analysis marketBased on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques.The flow cytometry segment accounted for the largest market share in 2018.

The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles.

North America will continue to dominate the single-cell analysis market in 2025The single-cell analysis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.In 2018, North America accounted for the largest share of the single-cell analysis market.

The large share of North America can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

The breakup of primary participants is as mentioned below: By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25% By Designation - C-level: 35%, Director-level: 25%, and Others: 40% By Region - North America: 40%, Europe: 20%, Asia Pacific: 25%, Latin America: 10%, and the Middle East & Africa: 5%

Prominent players in the single-cell analysis market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).

Research Coverage:The report analyzes the single-cell analysis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, cell type, technique, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights into: Market Penetration: Comprehensive information on the product portfolios of the top players in the single-cell analysis market. The report analyzes this market by product, application, cell type, technique, end user, and region Market Development: Comprehensive information on the lucrative emerging markets by product, application, cell type, technique, end user, and region Market Diversification: Exhaustive information about products, growing geographies, recent developments, and investments in the single-cell analysis market Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the single-cell analysis marketRead the full report: https://www.reportlinker.com/p04579530/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the rest here:
The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% - GlobeNewswire

Is Novavax, Inc. (NVAX) Stock Near the Top or Bottom of the Biotechnology Industry? – InvestorsObserver

Posted on by

Novavax, Inc. (NVAX) is near the top in its industry group according to InvestorsObserver. NVAX gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Novavax, Inc. gets a 76 rank in the Biotechnology industry. Biotechnology is number 24 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 63 means the stock is more attractive than 63 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Novavax, Inc. (NVAX) stock has gained 21.61% while the S&P 500 has fallen -2.35% as of 9:44 AM on Friday, Feb 28. NVAX has gained $2.55 from the previous closing price of $11.80 on volume of 1,278,132 shares. Over the past year the S&P 500 is higher by 4.47% while NVAX has gained 1.77%. NVAX lost -$7.12 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read the rest here:
Is Novavax, Inc. (NVAX) Stock Near the Top or Bottom of the Biotechnology Industry? - InvestorsObserver

Compass Therapeutics to Present at the 40th Cowen Health Care Conference – Business Wire

Posted on by

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 40th Annual Cowen Health Care Conference in Boston on Tuesday, March 3, 2020.

Dr. Schuetzs presentation will feature an update on the ongoing Phase 1 trial of the companys lead candidate, CTX-471, a fully human agonistic antibody of CD137 being evaluated in patients with advanced solid tumors. Dr. Schuetz will also share the companys progress on CTX-8371, a novel PD-1/PD-L1 bispecific, which has shown significantly increased activity in preclinical testing compared to PD-1 or PD-L1 monoclonal antibody therapies available commercially.

The presentation details are:

Date: Tuesday, March 3, 2020Time: 11:00 11:25 a.m. ETLocation: Boston Marriott Copley Place

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The companys lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The companys offices and labs are based in Kendall Square in Cambridge, Mass.

Continued here:
Compass Therapeutics to Present at the 40th Cowen Health Care Conference - Business Wire

Neurology | Neurology conferences | Neuro congress …

Posted on by

Advanced Neurology 2020

We are extremely gratified to declare our upcoming fortuitous neurology conference 4th World Congress on Neurology and TherapeuticsConference is scheduled during May 08-09, 2020 at Prague, Czech Republic.

It is our boundless privilege to solicit each one of you to our meritorious neuro meet of all the dignitaries worldwide over there. We believe in serving people with the most advanced solutions to Neurological Impairments where we stood prior in our last event 3rd World Congress on Neurology and Therapeutics Conference in Madrid, Spain. It was a tremendous success over the year to establish a strong affinity with our advanced neurological solutions, diagnosis and NeurotherapeuticsConference.

View our Past Conference Report of Advanced Neurology 2019 at https://neurology.pulsusconference.com/2019

Our propitious neurology congress is tailored around the theme Know the Unknown Advanced Solutions on Neurology

Weve constructed this years neurology conference primarily based on input from you, so get equipped for a streamlined agenda packed with neurologists, neurosurgeons, neuro specialists, neuro freaks, neuro physicians, industry insights, innovations, and masses of opportunities to share ideas and provide remarks.

Would like to give a glimpse of whats in:

Drop a line or note! it is all really worth to know from us.. neuromeet@pulsusgathering.com

Sincerely

Executive Director

Session on Neurology

The observe of neurons that is the functional unit of mind worries with the brains normal functioning, neural disorders, neural diagnosis and neurology treatment which incorporates each aspect about the condition of the ailment in our neurology conference. This place of interest offers with the backbone, the fearful gadget such as its masking, blood vessels, afferent and efferent tissues is thought to be neurology. A physician who specializes in neurology is known as a neurologist. The top neurologists treats troubles which have an effect at the brain, spinal cord, and nerves, which incorporates Cerebrovascular treatment, Spinal disorders and neurological disordersin various sessions of neurology conference.

Related Neurology Conferences | Neurology Conference | World Neurology Congress | Advanced Neurology Congress | Neurology meetings | Europe Neurology Conferences

Related Society & Associations Socit Franaise de Neurologie ; Croatian Neurological Society ; Finnish Neurological Association ; Cyprus Neurological Society ; Estonian Society of Neurologists & Neurosurgeons ; Czech Society of Neurology ; Danish Neurological Society ; Bulgarian Society of Neurology ; Albanian Society of Neurology ; Belgian Neurological Society ; Association of Azerbaijan Neurologists and Medical Geneticists ; Armenian Association of Neurologists

Session on Neurogenesis

The process of formation of the neuron cells from the predefined cells to the grownup neurogenesis is described as Neurogenesis. This mechanism takes area throughout embryogenesis by using the neural stem cells and progenitor cellsin our neurology conference. This mainly deals with the form and features of diverse varieties of science in neurology. via a chain of genetic mechanisms of mobile fate dedication, many unique types of excitatory and inhibitory neurons are made from exceptional kinds of neural stem cellsin every session of neurology conference. The boom method in area and evolution of practical matter. Our neurology conference moreover describes about the biophysical parameters of highbrow capability and new techniques for the development of neural cells in distinctive way of life medium.

Related Neurogenesis Conferences | Neurogenesis Congress | Neurogenetic meetings | Gliogenesis Conferences | Adult Neurogenesis Conference | Neurobiology Conference| Neurology Conference

Related Society & Associations Hellenic Association of Neurology ; Latvian Neurologists Association ; Hungarian Society of Neurology and Psychiatry ; Icelandic Neurological Society ; Societ Italiana di Neurologia ; Irish Institute of Clinical Neuroscience ; Norwegian Neurological Association ; Association of British Neurologists ; Turkish Neurological Society ; Polish Neurological Society ; Socit Suisse de Neurologie (Schweizerische Neurologische Gesellschaft) ; Portuguese Society of Neurology (Sociedade Portuguesa de Neurologia) ; Romanian Neurological Society ; All-Russian Society of Neurologists ; Yugoslav Neurological Society ; Slovenian Society of Neurology ; Sociedad Espaola de Neurologia ; Swedish Neurological Society (Svenska Neurologforeningen)

Session on Neurophysiology

The take a look at of nature and foundation of the brain which additionally issues with the functioning of the nervous system, frequently the use of the neurophysiological or molecular organic system that is the subspecialty of both the frame shape and Neuroscience as awesome regions of brain represent indicators to distinct elements of the body in neurology conference. This concern is counted need to deliver an extraordinary description of the revolutionized anatomy of the nervous system, the motor reaction manipulates neurons, perception processing, and reminiscence neurons. Neurology conferences discussions also can be made in neuromuscular physiology, neural mechanisms of higher nerve interest and troubles of Neuroscience also may be conferred in every session of neurology conference.

Related Neurophysiology Conferences | Neurophysiology Congress | Clinical Neurophysiology Conferences | Didactics Conferences | Neuroscience Conference | Prague Neurology events| Neurology Conferences

Related Society & Associations International Federation of Clinical Neurophysiology: IFCN ; American Clinical Neurophysiology Society ; The British Society for Clinical Neurophysiology ; Canadian Society of Clinical Neurophysiologists ; American Clinical Neurophysiology Society ; German Society for Clinical Neurophysiology and Functional Imaging (DGKN) ; The Italian Clinical Neurophysiology Society ; International Society of Intraoperative Neurophysiology (ISIN) ; Malaysian Society of Neuroscience (MSN) ; Clinical Neurophysiology Society of South Africa

Session on Clinical Neurology

Our series of neurology conferences deals with the sicknesses of the central nervous system consist of some of the most disabling situations, such as multiple sclerosis (MS), stroke, motor neuron disorder (MND), Alzheimers, Huntingtons and Parkinsons sickness like various other sub category in neurology conference. Those neurological disorders have been the threat to all the people who really strive to eradicate it and establish a healthy aging process and healthy environment for their circle of relatives and carers, and to society as an entire from this neurology conferences. We need to understand underlying neurological treatment with a purpose to treat these situations successfully. Neurology congress provides an appropriate setting to percentage facilities, know-how and as well as realise our purpose of making use of our studying in medical exercise

Related Clinical Neurology Conferences | Clinical Neurology Congress | Medical Neurology Conferences | Neurologists Conference | Neurological Sciences Conferences | Neuroscience Congress| Neurology Conference

Related Society & Associations Association of University Professors of Neurology ; Child Neurology Society ; Congress of Neurological Surgeons ; American Association of Neurological Surgeons ; American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) ; American Association of Neuropathologists ; American Association of Neuroscience Nurses ; American Brain Foundation ; American Epilepsy Society ; American Society for Experimental Neuro Therapeutics (ASENT) ; American Society for Neural Transplantation & Repair ; American Society for Neurochemistry ; American Society of Neuroimaging ; American Society of Neuroradiology ; American Society of Neurorehabilitation

Session on Neurological Nursing

Neuroscience nurses a very challenging nursing science contend with humans with diffusion of neurological conditions and issues throughout the lifespan and dealing with all health care settings amidst neurology conferences. The purpose of neurology events is to realize the nursing opportunities which have the ability to maximize consequences to prevent, to take care of the people with excessive neurological disorders. there are numerous neuro conferences specialities of encompassed internal this subject of practice collectively with (however now not constrained to) the subsequent: geriatric nursing, neurosurgery, neurotrauma, Neuroscience critical care, prolonged-time period neurological disorders, Parkinsons sickness, epilepsy, existence-limiting neurological disorders in our world neuro congress, e.g. motor neurone disorder, Huntingdons ailment especially in neurology pulsus conference.

Related Neurological Nursing Conferences | Neuroscience Nurse Conference | Neuro-nursing Congress | Neurosurgery nursing Conference | Nursing Conference Europe| Neurology Conferences

Related Society & Associations American Association of Neuroscience Nurses ; Association of Child Neurology Nurses ; British Association of Neuroscience Nurses (BANN) ; Canadian Association of Neuroscience Nurses ; Epilepsy Nurses Association ; East Coast Community Healthcare's Neurological Nursing Service ; Movement Disorder Society ; Association of University Professors of Neurology ; Child Neurology Society ; Congress of Neurological Surgeons ; International Brain Injury Association ; International Neuromodulation Society ; International Parkinson and Movement Disorder Society

Session on Neuropediatric

Neuropediatric is the branch of medication handling mental health, neurological disorders of children. The concern of Paediatric Neurology, additionally called Paediatric Neurology, encompasses issues of the brain, spinal twine, peripheral nerve and muscle affecting babies, youngsters and younger human beings in our neurology conference. The form of patients seen through paediatric neurologists varies from people with common, pretty sincere conditions, inclusive of cerebral palsy or migraine. This robust world neurology congress type of situation lets in Paediatric Neurologists to shape their medical or clinical careers in line with their scientific or studies pursuits from our neurology conferences. Paediatric neurogenetic issues are sicknesses of the mind, spinal cord, nerves and muscle tissues which can be resulting from modifications in genes or chromosomes. There are loads of neurogenetic disorders that could be discovered in every one among kind methods in every aspects of neurology conference.

Related Neurology Conferences | Neuro Paediatric Congress | Paediatric Neurology Congress | Nordic Neuropediatric Conference | Paediatric Neurology Conferences | Neurology Conferences Europe| Neurology Conferences

Related Society & Associations European Paediatric Neurology Society (EPNS) ; Child Neurology Society ; British Paediatric Neurology Association ; The Canadian Association Of Child Neurology ; Belgian Society of Pediatric Neurology ; American Society of Pediatric Neuroradiology ; International Society of Neuroimmunology ; Japanese Society for Neuroimmunology ; Italian Association of NeuroImmunology ; Indian Immunology Society ; International Society of Neuroimmunology ; Pediatric Society of Neuro-oncology ; German Neuropediatric Society ; Nordic Neuropediatric Society ; Scandinavian Neuropediatric Society

Session on Neuroimmunology

Neuroimmunology is an area of neuroscience, combining the immune system and the nervous systemin neurology conferences. The immune system administers defence in competition to those organisms, inefficiency of the equal consequences in Infections. Neuro Infections have been set up to sell outstanding affected individual care and research for immune and infectious issues of the apprehensive device through training of clinical and simple generation researchers, growing and offering diagnostic services, consultation services and supporting develop new modes of remedy from our keynotic presentations of neurology conference. Collectively our neurology conference offer understanding in several major immune and infectious disorders of the anxious system, consisting of Neuro-AIDS and other viral and opportunistic infections, poisonous Leuko-encephalopathies, Transverse myelitis and other myelopathies, GuillainBarr syndrome, persistent demyelinating polyneuropathy, Myasthenia gravis and different immune-mediated problems of the peripheral nervous systemeven more recent conditions from neurology conference.

Related Neuroimmunology Conferences | Neuroimmunology Congress | Neurology Events | Neuro infection Conference | Neurological Disorders Conference | Neurology Prague Events| Neurology Conferences

Related Society & Associations Austrian Society of Neurology (sterreichische Gesellschaft fr Neurologie) ; Georgian Society of Neurologists ; Socit Luxembourgeoise de Neurologie asbl ; Deutschen Gesellschaft fr Neurologie ; Lithuanian Neurological Society ; British Society For Clinical Neurophysiology ; The Physiological Society ; Neurological Sciences and Neurophysiology ; The International Neuropsychological Society ; British Peripheral Nerve Society ; International Society for Autism Research ; National Neurotrauma Society ; North American Spine Society ; Peripheral Nerve Society ; United Council for Neurologic Subspecialties

Session on Neuroplasticity

Neuroplasticity is also known as brain plasticity and neural plasticity that encompasses the 2 synaptic and non-synaptic plasticity and it refers to improve in neural pathways and synapses due to difference in behaviour, surroundings, neural strategies, wondering, and feelings similarly to changes due to physical are discussed in neurology conference. The goal of our neurology congress is to understand the brain plasticity advances in neurite transforming and the way to increase neural connections. Neurorehabilitation is a medical approach which goals to beneficial aid recovery from nervous system damage and to lessen or make amends for any practical alterations because of it.

Related Neuroplasticity Conferences | Cerebral Palsy Congress | Neuromodulation Conferences | Neurorehabilitation Conferences | Neurosciences Conferences Prague | Neurology Congress 2020| Neurology Conference

Related Society & Associations Socit Franaise de Neurologie ; Croatian Neurological Society ; Finnish Neurological Association ; Cyprus Neurological Society ; Estonian Society of Neurologists & Neurosurgeons ; Czech Society of Neurology ; Danish Neurological Society ; Bulgarian Society of Neurology ; Albanian Society of Neurology ; Belgian Neurological Society ; Association of Azerbaijan Neurologists and Medical Geneticists ; Armenian Association of Neurologists

Session on Neural Circuits ; Neural feedback

Neurofeedback (NFB), also called Neurotherapy, neurofeedback or EEG biofeedback is a form of biofeedback that makes use of actual-time shows of electroencephalography to demonstrate brain activity, frequently with an intention of controlling significant nervous system activity in our neurology conference. Through monitoring brain activity, its possible to teach our brain to provide specific cognitive function that can aid relaxation, help us be more inexperienced in our each day obligations, or offer non-pharmaceutical treatment for plenty conditions and issues is the vital role of neurology conference. Our neurologists, neuro conference participants are also neurofeedback practitioners and researchers who are pushed to promote excellence in scientific exercise, educational applications, and research in applied neuroscience to be able to better apprehend and enhance brain mechanism. Biofeedback therapy: uses and benefits: types, motive and dangers, Biofeedback device/devices, development of Biofeedback remedy, situations dealt with the usage of Biofeedback.

Related Neural Circuits Conference | Neurology Congress | Neurosurgery Congress Europe | Neurosurgeons Conference | Neuromodulation Conferences | Brain Behavior Conference| Neurology Conferences

Related Society and Associations International Society for Neurofeedback & Research ; The Association for Applied Psychophysiology and Biofeedback (AAPB); Western Association of Biofeedback and Neuroscience ; Society of Applied Neuroscience ; Applied Neuroscience society of Australasia (ANSA); Neurofeedback Society of UTSA ; Northeast Region Biofeedback Society (NRBS) ; Cognitive Neuroscience Society ; Mid-Atlantic Biofeedback Society ; International Society for Neuronal Regulation ; Mexican Society for Biofeedback and Neurofeedback (SMBN) ; Brandywine Valley Counselling and Neurofeedback Center ; The Biofeedback Society of Florida ; Autism Society Inland Empire ; Spanish Society of Bio and Neurofeedback (Sebine) ; Center for Academic and Psychological Services ; Autism Society Philippines ; Alpha Brain-Wave Neurofeedback Training ; Body Mind and Brain Neurotherapy Gold Coast

Session on Neurostimulation

The sector of Neurostimulation is present process notable increase, neuro activity stimulation strategies are suddenly reworking studies into brain mechanisms, from the molecular to the behavioral, and provide new strategies to therapeutics for neuro disorders. in lots of processes, the sector of brain stimulation represents a paradigm shift, augmenting and on occasion replacing the prominent psychopharmacological techniques of the beyond several a long time. Cognitive neuroscientists will mingle with neurosurgeons and brain modelling physicists. Neurology conference pass-disciplinary meeting will also offer the opportunity to have interaction with founders and luminaries within the neurology area.

Related Neurostimulation Conferences | Neurostimulation Congress | Neurostimulation Conference Carolina | Neurotransmission events | Neurology Conference Czech Republic | Neurology 2020

Related Society and Associations International Neuromodulation Society (INS) ; International Society for ECT and Neurostimulation (ISEN) ; Brazilian Medical Association ; Association of Pallidal Neurostimulation ; American Association for the Advancement of Science ; Neurological Societies Task Force on neurostimulation for pain ; Neuromodulation - Interstitial Cystitis Association ; Anxiety and Depression Association of America (ADAA)

Session on Neurotherapeutics ; Neuropharmacology

It's miles an older time period for the remedy of neurological disorders which have an impact on the brain mechanism and the nervous system which can be treated with certain therapeutic modalities and novel research that is ongoing in research activity. Neurotherapeutics session almost covers half of the world's advanced solutions for the neurological impairments, neurological disorders and what not to be added. There can be a profound boon within the gathering of our world neuro congress where diagnostics technique and drug discovery inside the area of Neurology and various allied sciences under neurology can be discussed. It consists of Stem cells and remedy, Nerve damage and restore clinical Case document, Neurogenesis, cell and gene-primarily based method and Neurotransmitter release and cell restore.

Related Neurotherapeutics Conference | Advanced Neurology Conference | Neurotherapeutic Symposium | Experimental Neurotherapeutics Conference | Neurology Conferences 2020

Related Society and Associations American Society for Pharmacology and Experimental Therapeutics (ASPET) ; Society on NeuroImmune Pharmacology ; Canadian Society of Pharmacology and Therapeutics (CSPT) ; Indian Pharmacological Society ; Japanese Society of Neuropsychopharmacology ; Australasian Society of Clinical and Experimental Pharmacologists ; International Union of Basic and Clinical Pharmacology (IUPHAR) ; International Behavioral Neuroscience Society ; American Society of Clinical Psychopharmacology (ASCP) ; Argentinean Society of Experimental Pharmacology ; American Society for Experimental Neurotherapeutics (ASENT)

Session on Neurological disorders ; Neurodegenerative disorders

Neurodegenerative disorders cause your mind and nerves to deteriorate through the years. They may be able to alternate your personality and reason confusion. They also can ruin your minds tissue and nerves. A few neuro disorders, such as Alzheimers disease, Parkinson's, Huntington's might, Dementia... also increase as you age. They may slowly impair your memory and idea strategies. Other neurological diseases, which incorporates Tay-Sachs ailment, are genetic and start at an early age. A neurological disorder is any turmoil inside the nervous system fundamental, biochemical or electrical irregularities inside the thoughts, spinal line or different nerves can bring about the neurology scope of manifestations. Neurology conferences relates all the cases of neurological manifestations incorporate lack of motion, muscle shortcoming, awful coordination, and lack of sensation, seizures, perplexity, torment and adjusted levels of awareness.

Related Neurological disorder Conference | Brain Disorder Conference | Neurology Conferences | Brain Disorder Conferences | Neurodegenerative Conferences |Neurology Meetings 2020

Related Society and AssociationsInternational Society for Neurofeedback & Research;The Association for Applied Psychophysiology and Biofeedback(AAPB);Western Association of Biofeedback and Neuroscience;Society of Applied Neuroscience;Applied Neuroscience society of Australasia(ANSA);Neurofeedback Society of UTSA;Northeast Region Biofeedback Society(NRBS) ;Cognitive Neuroscience Society;Mid-Atlantic Biofeedback Society;International Society for Neuronal Regulation;Mexican Society for Biofeedback and Neurofeedback(SMBN) ;Brandywine Valley Counselling and Neurofeedback Center;The Biofeedback Society of Florida;Autism Society Inland Empire;Spanish Society of Bio and Neurofeedback(Sebine) ;Center for Academic and Psychological Services;Autism Society Philippines;Alpha Brain-Wave Neurofeedback Training;Body Mind and Brain Neurotherapy Gold Coast

Session on Neuromuscular Disorders

Neuromuscular disorders are the illnesses which impair the functioning of muscle groups each right now via affecting the voluntary muscle groups or with the resource of affecting the nerves system or neuromuscular junctions. revolutionary muscle weak factor is the condition in those neurological disorders. Neuromuscular disorders may be labelled as ailments of the Neuromuscular disorders, neuron cellular problems, Motor neuron disorder and so on. so as to diagnose these sicknesses, Electromyography should be used, inside the route of Electromyography, small electric impulses are given to the nerves and electric responses are recorded. This allows discovering the lack of nerve fibres and problems of insulation of nerves. Neuromuscular conference allows to interpret in these criterias all along the neurology conference in Prague.

Related Neuromuscular Disorder Conferences | Annual Neurology Congress | Neuromuscular Conferences | Neurology Conferences | Neurology 2020 Europe Conferences

Related Society & Associations Hellenic Association of Neurology ; Latvian Neurologists Association ; Hungarian Society of Neurology and Psychiatry ; Icelandic Neurological Society ; Societ Italiana di Neurologia ; Irish Institute of Clinical Neuroscience ; Norwegian Neurological Association ; Association of British Neurologists ; Turkish Neurological Society ; Polish Neurological Society ; Socit Suisse de Neurologie (Schweizerische Neurologische Gesellschaft) ; Portuguese Society of Neurology (Sociedade Portuguesa de Neurologia) ; Romanian Neurological Society ; All-Russian Society of Neurologists ; Yugoslav Neurological Society ; Slovenian Society of Neurology ; Sociedad Espaola de Neurologia ; Swedish Neurological Society (Svenska Neurologforeningen)

Session on Neurosurgery

Medical and Surgical examination which offers with the treatment of neurological problems, neural disorders, blood clots, and many other specific neurology issues related to the brain, spinal cord, peripheral nerves, central nervous and in addition operating the cranial cerebrovascular system is coined to Neurosurgery. Emergencies like intracranial haemorrhage and neurotrauma are essentially involved in most of the neurosurgery. some of the scientific sessions of neurosurgery conference includes vascular neurosurgery and endovascular neurosurgery, stereotactic neurosurgery, beneficial neurosurgery, and epilepsy surgery, mind tumor, oncological neurosurgery, skull base surgical treatment, spinal neurosurgery, peripheral nerve surgical operation. Neurosurgery is a whole-time dedication to treating patients with neurological disorders and to the search for better therapies, cures and investigates the most promising advances in neuroscience research, and train tomorrow's leaders in neurosurgery.

Related Neurosurgery Conference | Neurosurgery Conferences | Neurosurgeons gathering | World Neuro Congress |Neurology Congress 2020 | Neurology Prague conferences

Related Society & Associations International Federation of Clinical Neurophysiology: IFCN ; American Clinical Neurophysiology Society ; The British Society for Clinical Neurophysiology ; Canadian Society of Clinical Neurophysiologists ; American Clinical Neurophysiology Society ; German Society for Clinical Neurophysiology and Functional Imaging (DGKN) ; The Italian Clinical Neurophysiology Society ; International Society of Intraoperative Neurophysiology (ISIN) ; Malaysian Society of Neuroscience (MSN) ; Clinical Neurophysiology Society of South Africa

Session on Neuroimaging ; Radiology

Neuroradiology performs a vital position inside the prognosis and characterization of various Neurological disorders. Neurology conferences entails amazing sorts of Imaging studies collectively with Computed Tomography (CT) and Magnetic Resonance Imaging (MRI). simple Radiography and Ultrasound are used in a confined foundation especially in Pediatric population. Neuroimaging is the mapping of the human mind the usage of purposeful Magnetic Resonance Imaging (fMRI). Neuroimaging determines the association among brain mechanism elements and health influence on mind growing older at some level within the person lifespan. Neuroimaging determines how difference and trade-in Cerebral structure, complexly relates to behaviour and Cognition at a couple of levels of analysis. Neurology Conference brings collectively various topics of interests consisting of practical Neuroimaging, Cognitive Neuroscience, and Cognitive mechanism models.

Related Neuroimaging Conferences | Neuroimaging Congress | Neuroradiology meetings | Neurology Conferences | Neurology Congress | Advanced Neurology Conferences |Neurology 2020

Related Society & Associations Association of University Professors of Neurology ; Child Neurology Society ; Congress of Neurological Surgeons ; American Association of Neurological Surgeons ; American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) ; American Association of Neuropathologists ; American Association of Neuroscience Nurses ; American Brain Foundation ; American Epilepsy Society ; American Society for Experimental Neuro Therapeutics (ASENT) ; American Society for Neural Transplantation & Repair ; American Society for Neurochemistry ; American Society of Neuroimaging ; American Society of Neuroradiology ; American Society of Neurorehabilitation

Session on Psychology ; Psychiatry

Exploration of neurology or all of those questions has been and is being undertaken in such disciplines as cognitive psychology, neuro linguistics, philosophy, artificial intelligence, robotics, neuroscience, training, cognitive sciences, behavioural economics, and others. The fundamentals and the minor in Cognitive science, neurology conferences consequently, constitute a proper means of bringing collectively students and neuro physicians in exclusive disciplines who percentage common interests. From our neurology conference, we are seeking to enhance the view supplied by way of every person discipline through exploration or the methodologies of Neurology. Interdisciplinary group of psychiatrists, clinical psychologists, forensic psychologists, neuropsychologists, occupational psychologists and health psychologists based within the Institute of Mental Health and enjoying close links with topics related to the neurosciences and the behavioural sciences.

Related Psychology Conferences | Psychology Congress | Psychiatry Conferences | Psychiatry Meetings | Psychiatry Conferences | Neurology Conferences

Related Society & Associations American Association of Neuroscience Nurses ; Association of Child Neurology Nurses ; British Association of Neuroscience Nurses (BANN) ; Canadian Association of Neuroscience Nurses ; Epilepsy Nurses Association ; East Coast Community Healthcare's Neurological Nursing Service ; Movement Disorder Society ; Association of University Professors of Neurology ; Child Neurology Society ; Congress of Neurological Surgeons ; International Brain Injury Association ; International Neuromodulation Society ; International Parkinson and Movement Disorder Society

Session on Behavioural Sciences

The study of the relationship between behavior, emotion, and cognition on the one hand, and brain feature on the other. Neuropsychology research the shape and characteristic of the mind as they relate to unique mental strategies and behaviours. medical neuropsychology is a uniqueness in professional psychology that applies standards of evaluation and intervention primarily based upon the medical look at human behavior because it pertains to normal and unusual functioning of the relevant nervous system. The robust factor of neurology congress is dedicated to improving the of brainbehaviour relationships and the software program of such understanding to human troubles.

Related Behavioral Science Conferences | Behavioral Neuroscience Conferences | Cognitive Sciences | Cognitive Neuroscience Conferences | Cognitive Conferences | Behavioral Neurology Conferences

Related Society & Associations European Paediatric Neurology Society (EPNS) ; Child Neurology Society ; British Paediatric Neurology Association ; The Canadian Association Of Child Neurology ; Belgian Society of Pediatric Neurology ; American Society of Pediatric Neuroradiology ; International Society of Neuroimmunology ; Japanese Society for Neuroimmunology ; Italian Association of NeuroImmunology ; Indian Immunology Society ; International Society of Neuroimmunology ; Pediatric Society of Neuro-oncology ; German Neuropediatric Society ; Nordic Neuropediatric Society ; Scandinavian Neuropediatric Society

Session on Clinical trials, case studies and recent researches

The Web Directory

Best Advertising Platform, Discover Fantastic Sites, Excellent Online Advertising, Best Web-based Marketing, Market Your Websites Online

Nctweb Web Directory

TargetsViews Free Links Web Directory

web directory

Picktu Directory

TargetsViews Free Links Web Directory

LinkPedia Web Directory

Interesting Dir

With utmost appreciation, Advanced Neurology 2019 thanks all the participants for their sincere efforts to place our 3rd World Congress on Neurology and Therapeutics, October 07-08, 2019 in Madrid, Spain a successful and memorable one.

In a row of series, Pulsus Group has completed over three international Neurology conferences. We would really like to thank all of our outstanding dignitaries of world neuro congress for presenting us with the splendid keynotes, speakers, convention attendees, students, institutions, media partners and guests for making Advanced Neurology 2019 a success and top-notch event.

Pulsus Group hosted the 3rd World Congress on Neurology and Therapeutics during October 07-08, 2019 in Madrid, Spain at Rafaelhoteles Forum Alcal with the theme Neurology! Heal the world of Neurological Impairments... Benevolent response and active participation was received from the Editorial Board Members of supporting International Journals as well as from the leading academic scientists, researchers, research scholars, students and leaders from the fields of Neurology, Neuroscience and neurotherapeutics who made this event successful.

The neurology conference turned into marked with the aid of the attendance of young and brilliant researchers, enterprise delegates and talented pupil communities representing greater nations, who've driven this event into the path of achievement. This neurology conference highlighted through diverse periods on Neurological issues studies.

Advanced Neurology 2019 witnessed an amalgamation of unparalleled speakers who enlightened the gathering with their knowledge and discussed on various new-fangled topics related to the fields of Neurological Disorders, Neurotherapeutics, Neuro-imaging, Neurology, Neuroscience.

The neurology congress proceedings were performed through various scientific sessions and plenary lectures. Neurology conference changed into embarked with an opening ceremony accompanied by way of a sequence of lectures introduced by way of both Honourable guests and contributors to the Keynote discussion board.

Jacques Fantini | Aix-Marseille University | France

Nouara Yahi | Aix-Marseille University | France

Originally posted here:
Neurology | Neurology conferences | Neuro congress ...

Study Finds Artisanal CBD Not as Effective as Pharmaceutical CBD for Reducing Seizures – Southernminn.com

Posted on by

MINNEAPOLIS, Feb. 28, 2020 /PRNewswire/ --Children and teens with epilepsy who were treated with pharmaceutical cannabidiol (CBD) had much better seizure control than those who were treated with artisanal CBD, according to a preliminary study to be presented at the American Academy of Neurology's 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020.

CBD is a cannabis component that relieves stress and anxiety and has anti-seizure properties. It does not produce a "high" like another cannabis component called tetrahydrocannabinol (THC). Pharmaceutical CBD for epilepsy does not have THC. It is FDA approved for use in two severe forms of childhood epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, which do not respond well to other medications. Artisanal CBD is manufactured using varying techniques and contains variable amounts of CBD and THC.

"The use of medical cannabis to treat various medical conditions has grown in recent years. While not always legal, artisanal CBD has been available longer, so some people have been using it to treat epilepsy for years," said study author Nathan T. Cohen, M.D., of Children's National Hospital in Washington D.C., and a member of the American Academy of Neurology. "They may want to reconsider because our research indicates that pharmaceutical CBD may indeed be more effective than artisanal CBD."

For the study, researchers reviewed the medical charts of 31 children and teens with an average age of 10 who were followed for an average age of one year. All had some form of epilepsy including 32% with Lennox-Gastaut syndrome and 6% with Dravet syndrome. Of the group, 22 were taking pharmaceutical CBD and nine were taking artisanal CBD. Researchers recorded medication doses, levels of CBD in the blood, seizure history and reduction in seizures with medication and side effects.

Those taking artisanal CBD had an average level of CBD in the blood of 31 nanograms per milliliter (ng/mL) compared to 124 ng/mL for those taking pharmaceutical CBD.

Researchers found children and teens taking artisanal CBD had a 70% increase in seizures during the study. Those taking prescription CBD had a 39% reduction in seizures.

However, 11 participants reported side effects. All were taking pharmaceutical CBD. Side effects included sleepiness, low appetite, nausea and diarrhea. Six of those participants stopped taking pharmaceutical CBD due to side effects.

"The difference in seizure control is dramatic and is definitely of concern since many people continue to use artisanal CBD," said Cohen. "However, a limitation of our study is that it was small. More research is needed to see if similar results are found in larger groups of people."

Another limitation of the study was that it was a look back at medical records. It did not involve participants who were given either pharmaceutical or artisanal CBD and then followed over time.

Learn more about epilepsy at BrainandLife.org, home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with more than 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Read this article:
Study Finds Artisanal CBD Not as Effective as Pharmaceutical CBD for Reducing Seizures - Southernminn.com

Shared Genetic Variants Associated With Migraine and Multiple Sclerosis – Neurology Advisor

Posted on by

WEST PALM BEACH, FL Migraine prevalence was significantly higher among patients with multiple sclerosis (MS) compared with healthy controls, with several genetic variants being shared between migraine and MS, according to research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2020 Forum held from February 27 to 29, 2020, in West Palm Beach, Florida. Several variants were found to increase migraine risk but decrease MS risk; these findings may lead to improvements in targeted treatments and therapies.

Although symptoms and risk factors for migraine and MS often overlap, and up to 69% of patients with MS suffer migraine, it is unknown whether these 2 disorders are independent or have a common biological etiology, such as genetics. The current study used data on 1094 patients with MS and 12,176 control participants who were Kaiser Permanente Northern California Health Plan members to investigate if any genetic variants independently associated with migraine or MS could be identified from genome-wide association studies that are shared between both conditions.

Migraine status was determined via self-report and validated electronic health record algorithm. Prior genome-wide association studies of MS or migraine were used to identify variants, and after quality control, investigators analyzed 902 variants with minor allele frequency greater than 1%. Observed and permuted P for each phenotype were obtained from logistic regression and compared with identify variants associated with both phenotypes. Logistic regression models were adjusted for sex and ancestry among any variants that had significant associations with both phenotypes.

The migraine model was adjusted for a propensity score representing the probability of MS case-control status to account for potential ascertainment bias from obtaining a secondary phenotype from a case-control study.

Among the 1094 patients with MS, the mean age was 49.95 years old (SD=9.02) compared with 49.01 years old (SD=8.92) for controls. Women made up 79.98% of MS cases and 80.60% of controls. Median MS Severity Score was 3.21 (SD=2.43). Migraine incidence was significantly higher (P <.05) among MS cases (40%) compared with controls (29%). Preliminary results found 5 genetic variants (rs6677309, rs10801908, rs1335532, rs62420820, and rs17066096) that were significantly associated (P <.05) with both MS and migraine. Three of these were protective for MS (rs6677309, rs10801908, and rs1335532), and all variants increased odds of migraine.

Study investigators concluded, Results showed the prevalence of migraine was significantly higher among individuals with MS compared [with] healthy controls.Several genetic variants were shared between MS and migraine, and implicated genes include CD58, which modulates regulatory T-cells, and several immune genes (IL20RA, IL22RA2, IFNGR1 and TNFAIP3) within the 6q23 chromosomal region. Because several variants increase risk of migraine but decrease risk of MS, there may be implications for targeted therapies and treatments.

Visit Neurology Advisors conference section for continuous coverage from the ACTRIMS 2020 Forum.

Reference

Horton M, Robinson S, Shao X, et al. Discovery of shared genetic variants associated with multiple sclerosis and migraine. Presented at: 5th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum; February 27-29, 2020; West Palm Beach, FL. Abstract P140.

Go here to see the original:
Shared Genetic Variants Associated With Migraine and Multiple Sclerosis - Neurology Advisor

Patients Receiving Treatment for MS Have Increased Risk for Any Infection – Neurology Advisor

Posted on by

WEST PALM BEACH Patients who have been diagnosed with and treated for multiple sclerosis (MS) have an increased risk for any type of infection, and are more frequently hospitalized because of infections compared with their health counterparts, according to research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2020 Forum held from February 27 to 29, 2020, in West Palm Beach, Florida. Results further showed that the highest increased risk was associated with renal tract infection.

Previous research has suggested that patients with MS have an increased risk for infection; therefore, the current study was designed to describe infection rates in this patient population using data from the United States Department of Defense database. Patients who were diagnosed with MS >1 year ago and were receiving treatment for this illness between January 2004 and August 2017 (n=8695) were matched with control patients without MS (n=86,934) by sex, age, and geographic region. Infections recorded after MS diagnosis were identified and incidence rates and incidence rate ratios (IRRs) of infection type and first infection were calculated.

During a median 7 years of follow-up, participants with MS had higher infection rates (any infection, diagnoses combined) (IRR, 1.76; 95% CI, 1.72-1.80) and hospitalized infections (IRR, 2.43; 95% CI, 2.23-2.63). Compared with matched controls, patients with MS had a higher incidence rate of first renal tract infection (IRR, 1.88; 95% CI, 1.81-1.95); skin infections (IRR, 1.51; 95% CI, 1.45-1.58); fungal infections (IRR, 1.47; 95% CI, 1.41-1.53); pneumonia and influenza (IRR, 1.48; 95% CI, 1.40-1.56); as well as other types of infection including helminthiases, rickettsioses, spirochetal diseases, nonsyphilitic and nongonococcal venereal diseases, and parasitic infections and infestations (IRR, 1.68; 95% CI, 1.61-1.75).

Incidence rate ratios of eye, ear, respiratory, throat, and viral infections were only marginally elevated. Results also demonstrated that rates of renal tract infections were more than 4-fold higher among women compared with men in both groups, but the IRR was higher in men (IRR, 2.47; 95% CI, 2.22-2.75) than women (IRR, 1.90; 95% CI, 1.83-1.98).

The investigators concluded, Treated MS patients have an increased risk of any infections. Hospitalized infections were also increased in MS patients. Most infection types were increased in MS patients with the highest risk associated with renal tract infections.

Visit Neurology Advisors conference section for continuous coverage from the ACTRIMS 2020 Forum.

Reference

Jick S, Persson R, Ulcickas M, et al. Increased risk of infections in patients diagnosed with and treated for multiple sclerosis: A study using the US Department of Defense Database. Presented at: ACTRIMS Forum 2020; February 27-29, 2020; West Palm Beach, FL. Abstract P086.

Excerpt from:
Patients Receiving Treatment for MS Have Increased Risk for Any Infection - Neurology Advisor